Skip to content
DataLookout
Menu

NCT05673148

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 28 versions: 27 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 189 → 195 locations
  2. Notable Eligibility criteria shortened, about 5 words
    • Study sites: 187 to 189
    • Secondary endpoints: details revised at 3 of 3 entries
    • Publications: details revised at 2 of 2 entries
  3. Notable Enrollment reduced: 364 → 146 participants
    • Phase changed: Phase 3 → Phase 2
    • Site details revised at 11 of 187 sites
    v26
  4. Notable Phase: Phase 3 to Phase 2v25 Show 5 more changesShow less
    • Enrollment target: 364 to 146
    • Eligibility criteria expanded, about 315 words
    • Study description expanded, about 44 words
    • Site details revised at 1 of 187 sites
    • Study title shortened, about 1 word
  5. Minor Study sites: 186 to 187v24
Show 21 earlier versionsHide 21 earlier versions
  1. Minor Study sites: 185 to 186v23
  2. Minor Study sites: 183 to 185v22
  3. Minor Study sites revised (183)v21
  4. Minor Study sites: 182 to 183v20
  5. Minor Site details revised at 8 of 182 sitesv19
  6. Minor Study sites: 177 to 182v18
  7. Minor Study sites: 176 to 177v17
  8. Minor Site details revised at 3 of 176 sitesv16
  9. Minor Study sites: 166 to 176v15
  10. Minor Study sites: 148 to 166v14
  11. Minor Study sites: 130 to 148v13
  12. Notable Start date: Jan 10, 2023 to Oct 9, 2023
    • Primary completion date: Jun 3, 2028 to Jul 3, 2028
    • Site details revised at 125 of 130 sites
    v12
  13. Minor Study sites: 125 to 130v11
  14. Minor Study sites: 116 to 125v10
  15. Minor Study sites: 108 to 116v9
  16. Minor Study sites revised (108)v8
  17. Minor Study sites: 97 to 108v7
  18. Minor Study sites: 82 to 97v6
  19. Minor Study sites: 59 to 82v5
  20. Minor Study sites: 11 to 59v4
  21. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 11
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Overall Survival (OS)
Timeframe: From the date of randomization to the date of death due to all causes, assessed up to 5 years

Secondary (3)

Event Free Survival (EFS)
• Incidence of Adverse Events (AEs), assessed using National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) version 5.0 (v5.0)
Time to local recurrence (TLR)

Arms and interventions

Arm 1 (TAT, SOC chemotherapyExperimental

Patients undergo TAT on study, consisting of SABR with or without surgical resection and/or microwave ablation. Patients also receive SOC chemotherapy on study. Patients also undergo CT or MRI or PET/CT scans throughout the trial.

Arm 2 (SOC chemotherapy)Active comparator

Patients receive SOC chemotherapy on study. Patients also undergo Patients also undergo CT or MRI or PET/CT scans throughout the trial.

Procedures: Stereotactic Ablative Radiotherapy, Resection, Microwave Ablation, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography

Drugs: Chemotherapy

Sites

195 sites in 2 countries

United States 194, Canada 1